StratDeck

Two stocks in Healthcare

Fresenius SE & Co. KGaA vs Genmab A/S: profit, growth, debt and price compared

Genmab A/S is stronger on 3 of 6 figures: profit margin, sales growth and price trend. Fresenius SE & Co. KGaA is stronger on 2: debt and price for its expected profit.

Figures as of 18 November 2026Yahoo Finance
Explore Fresenius SE & Co. KGaA's storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Fresenius SE & Co. KGaA and Genmab A/S side by side
Fresenius SE & Co. KGaAFRE.DEGenmab A/SGMAB.CO
Net margin6.6%Stronger: 17.0%
Revenue growth, past year+5.90%Stronger: +16.10%
Debt to equityStronger: 57.0%82.1%
Forward P/EStronger: 13.7×29.9×
Dividend yield1.95%—
AnalystsStrong buy · 14Strong buy · 13
From its 200-day average+19.2%Stronger: +54.9%

Share price over the past year

  • Fresenius SE & Co. KGaA+14.2%
  • Genmab A/S+78.6%

20 Nov 202518 Nov 2026

Fresenius SE & Co. KGaA or Genmab A/S: which is stronger?

  • GMAB.CO

    Which is more profitable?

    Genmab A/S keeps more of each sale as profit: 17.0% against 6.6%.

  • GMAB.CO

    Which is growing its sales faster?

    Genmab A/S is growing its sales faster: +16.10% over the past year, against +5.90%.

  • FRE.DE

    Which has borrowed less?

    Fresenius SE & Co. KGaA has borrowed less: its debt is 57.0% of what its shareholders own, against 82.1% for Genmab A/S.

  • FRE.DE

    Which costs less for the profit it is expected to make?

    Fresenius SE & Co. KGaA costs less for the profit it is expected to make: 13.7× its forward earnings, against 29.9×.

  • Which do analysts rate higher?

    Analysts rate both the same: Strong buy.

  • GMAB.CO

    Which is in the stronger price trend?

    Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 19.2% above.

What each company does

FRE.DEFresenius SE & Co. KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa.

Reports results on 24 February 2027

GMAB.COGenmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

Reports results on 16 February 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.